A phase Ib, open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending oral doses of Rimeporide in patients with Duchenne Muscular Dystrophy
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2017
At a glance
- Drugs Rimeporide (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Acronyms Rim4DMD
- Sponsors Merck Serono
- 26 Jul 2017 Planned End Date changed from 30 Mar 2017 to 1 Dec 2017.
- 26 Jul 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Dec 2017.
- 17 Nov 2015 New trial record